Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > I actually felt FOMO today
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Mole101on Feb 08, 2021 9:47pm
156 Views
Post# 32508871

RE:I actually felt FOMO today

RE:I actually felt FOMO todayThis buying tells me that the big boys are coming in fast ..

House  Bought  Sold  Net 
House 001
Anonymous
Bought $972,853
Volume 217,880
Average $4.465
Sold $607,149
Volume 133,514
Average $4.547
Net $365,704
Volume 84,366
 
House 089
Raymond James
Bought $235,835
Volume 56,800
Average $4.152
Sold $21,750
Volume 5,000
Average $4.350
Net $214,085
Volume 51,800
 
House 033
Canaccord
Bought $176,035
Volume 40,716
Average $4.323
Sold $14,901
Volume 3,349
Average $4.449
Net $161,134
Volume 37,367
 
House 014
ITG
Bought $62,424
Volume 13,600
Average $4.590
Sold 0
Volume 0
Average 0

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities